New Journal Website is available at:

Published by: Kowsar

Lower Doses of Bosentan in Combination With Sildenafil Might be Beneficial in Pulmonary Arterial Hypertension

Ahmad Amin 1 , * , Arezoo Mohamadifar 1 , Sepideh Taghavi 1 , Nasim Naderi 1 and Hosnolah Sadeghi 1
Authors Information
1 Rajaie Cardiovascular, Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran
Article information
  • Research in Cardiovascular Medicine: August 2015, 4 (3); e26487
  • Published Online: August 1, 2015
  • Article Type: Research Article
  • Received: December 29, 2014
  • Revised: April 16, 2015
  • Accepted: April 25, 2015
  • DOI: 10.5812/cardiovascmed.26487v2

To Cite: Amin A, Mohamadifar A, Taghavi S, Naderi N, Sadeghi H. et al. Lower Doses of Bosentan in Combination With Sildenafil Might be Beneficial in Pulmonary Arterial Hypertension, Res Cardiovasc Med. 2015 ;4(3):e26487. doi: 10.5812/cardiovascmed.26487v2.

Copyright: Copyright © 2015, Research in Cardiovascular Medicine. .
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009; 53(17): 1573-619[DOI][PubMed]
  • 2. Galiè N, Grigioni F, Bacchi Reggiani L. Relation of endothelin-1 to survival in patients with primary pulmonary hypertension. Eur J Clin Invest . 1996; 26
  • 3. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993; 328(24): 1732-9[DOI][PubMed]
  • 4. Yamane K. Endothelin and collagen vascular disease: a review with special reference to Raynaud's phenomenon and systemic sclerosis. Intern Med. 1994; 33(10): 579-82[PubMed]
  • 5. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002; 346(12): 896-903[DOI][PubMed]
  • 6. A. T. S. Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories . ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002; 166(1): 111-7[DOI][PubMed]
  • 7. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2000; 161(2 Pt 1): 487-92[DOI][PubMed]
  • 8. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002; 40(4): 780-8[PubMed]
  • 9. Paciocco G, Martinez FJ, Bossone E, Pielsticker E, Gillespie B, Rubenfire M. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur Respir J. 2001; 17(4): 647-52[PubMed]
  • 10. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001; 358(9288): 1119-23[DOI][PubMed]
  • 11. Nishikawa-Takahashi M, Ueno S, Kario K. Long-term advanced therapy with bosentan improves symptoms and prevents deterioration of inoperable chronic thromboembolic pulmonary hypertension. Life Sci. 2014; 118(2): 410-3[DOI][PubMed]
  • 12. Surie S, Reesink HJ, Marcus JT, van der Plas MN, Kloek JJ, Vonk-Noordegraaf A, et al. Bosentan treatment is associated with improvement of right ventricular function and remodeling in chronic thromboembolic pulmonary hypertension. Clin Cardiol. 2013; 36(11): 698-703[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader